Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies.

Lionaki S, Liapis G, Boletis JN.

Medicina (Kaunas). 2019 Jul 11;55(7). pii: E365. doi: 10.3390/medicina55070365. Review.

2.

Impact of Primary Disease Nature in the Development of De Novo Donor-Specific Antibodies After Kidney Transplant and the Risk of Acute Rejection.

Lionaki S, Pappas A, Altanis N, Kapsia H, Liapis G, Vittoraki A, Iniotaki A, Zavos G, Boletis JN.

Exp Clin Transplant. 2019 Jun;17(3):304-312. doi: 10.6002/ect.2018.0054. Epub 2018 Oct 24.

3.

Primary Hepatic Burkitt Lymphoma in a Kidney Transplant Recipient.

Lionaki S, Tsakonas E, Androulaki A, Liapis G, Panayiotidis P, Zavos G, Boletis JN.

Case Rep Nephrol. 2018 May 13;2018:7425785. doi: 10.1155/2018/7425785. eCollection 2018.

4.

Stress and Disease Onset in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Golemati CV, Mavragani CP, Lionaki S, Karaiskos D, Moutsopoulos HM.

Front Psychiatry. 2017 Dec 15;8:286. doi: 10.3389/fpsyt.2017.00286. eCollection 2017.

5.

Central nervous system involvement in patients with granulomatosis with polyangiitis: a single-center retrospective study.

Fragoulis GE, Lionaki S, Venetsanopoulou A, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzioufas AG.

Clin Rheumatol. 2018 Mar;37(3):737-747. doi: 10.1007/s10067-017-3835-y. Epub 2017 Sep 15.

PMID:
28914375
6.

The clinical course of IgA nephropathy after kidney transplantation and its management.

Lionaki S, Panagiotellis K, Melexopoulou C, Boletis JN.

Transplant Rev (Orlando). 2017 Apr;31(2):106-114. doi: 10.1016/j.trre.2017.01.005. Epub 2017 Feb 2. Review.

PMID:
28209246
7.

Cyclophosphamide followed by rituximab for aggressive multiple-relapsing antineutrophil cytoplasmic antibody-associated vasculitis.

Lionaki S, Fragoulis GE, Venetsanopoulou A, Vlachoyiannopoulos P, Boletis JN, Tzioufas AG.

Clin Exp Rheumatol. 2017 Mar-Apr;35 Suppl 103(1):155-164. Epub 2017 Jan 25.

PMID:
28134075
8.

The Prevalence and Management of Pauci-Immune Glomerulonephritis and Vasculitis in Western Countries.

Lionaki S, Boletis JN.

Kidney Dis (Basel). 2016 Mar;1(4):224-34. doi: 10.1159/000442062. Epub 2015 Dec 5. Review.

9.

Understanding the complement-mediated glomerular diseases: focus on membranoproliferative glomerulonephritis and C3 glomerulopathies.

Lionaki S, Gakiopoulou H, Boletis JN.

APMIS. 2016 Sep;124(9):725-35. doi: 10.1111/apm.12566. Epub 2016 Jun 30. Review.

PMID:
27356907
10.

Predictors of renal histopathology in antineutrophil cytoplasmic antibody associated glomerulonephritis.

Lionaki S, Mavragani CP, Karras A, Liapis G, Somarakis G, Boletis JN, Drosos A, Tzioufas AG, Guillevin L, Moutsopoulos HM.

J Autoimmun. 2016 Aug;72:57-64. doi: 10.1016/j.jaut.2016.05.004. Epub 2016 May 15.

PMID:
27194577
11.

Patients with primary membranous nephropathy are at high risk of cardiovascular events.

Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH.

Kidney Int. 2016 May;89(5):1111-1118. doi: 10.1016/j.kint.2015.12.041. Epub 2016 Feb 26.

PMID:
26924046
12.

A Cytomegalovirus-related Pseudotumor in the Colon of A Renal Transplant Recipient Shrunk by Antiviral Therapy.

Lionaki S, Altanis N, Papaxoinis K, Delladetsima I, Daikos G, Boletis JN.

Transplantation. 2015 Jul;99(7):e46-7. doi: 10.1097/TP.0000000000000772. No abstract available.

PMID:
26147137
13.

Urine NGAL as a biomarker of kidney damage after on- and off-pump coronary artery bypass graft surgery: a prospective pilot study.

Karaolanis G, Katsaros A, Palla VV, Lionaki S, Moris D, Karanikola E, Kravaritou M, Drossos V, Psarros T, Triantafillou K, Aleksandropoulos N, Zografos G.

Hellenic J Cardiol. 2015 Mar-Apr;56(2):160-8.

14.

Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: a single center experience.

Lionaki S, Vlachopanos G, Georgalis A, Liapis G, Skalioti C, Zavos G, Boletis JN.

Ren Fail. 2015 Jun;37(5):777-83. doi: 10.3109/0886022X.2015.1015366. Epub 2015 Feb 26.

PMID:
25715638
15.

Clostridium difficile infection among kidney transplant recipients: frequency, clinical presentation, and outcome.

Lionaki S, Panagiotellis K, Moris D, Daikos G, Psyhogiou M, Vernadakis S, Zavos G, Boletis JN.

APMIS. 2015 Mar;123(3):234-9. doi: 10.1111/apm.12348. Epub 2014 Dec 31.

PMID:
25556694
16.

Kidney transplantation in patients with systemic lupus erythematosus.

Lionaki S, Skalioti C, Boletis JN.

World J Transplant. 2014 Sep 24;4(3):176-82. doi: 10.5500/wjt.v4.i3.176. Review.

17.

Secondary hyperoxaluria: a risk factor for kidney stone formation and renal failure in native kidneys and renal grafts.

Karaolanis G, Lionaki S, Moris D, Palla VV, Vernadakis S.

Transplant Rev (Orlando). 2014 Oct;28(4):182-7. doi: 10.1016/j.trre.2014.05.004. Epub 2014 May 27. Review.

PMID:
24999029
18.

Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure.

Lee T, Gasim A, Derebail VK, Chung Y, McGregor JG, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Nachman PH.

Clin J Am Soc Nephrol. 2014 May;9(5):905-13. doi: 10.2215/CJN.08290813. Epub 2014 Feb 27.

19.

Kidney transplantation outcomes from expanded criteria donors, standard criteria donors or living donors older than 60 years.

Lionaki S, Kapsia H, Makropoulos I, Metsini A, Skalioti C, Gakiopoulou H, Zavos G, Boletis JN.

Ren Fail. 2014 May;36(4):526-33. doi: 10.3109/0886022X.2013.876348. Epub 2014 Jan 23.

PMID:
24456131
20.

Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation.

Lionaki S, Panagiotellis K, Iniotaki A, Boletis JN.

Clin Dev Immunol. 2013;2013:849835. doi: 10.1155/2013/849835. Epub 2013 Nov 21. Review.

Supplemental Content

Loading ...
Support Center